What began as a scientific pursuit has evolved into a robust technology platform grounded on archaeal tetraether lipids produced through our proprietary, patented processes.
Austria’s Biotech Future in Focus: NovoArc Hosts Federal Leaders
NovoArc GmbH had the honor of welcoming Federal Minister Dr. Wolfgang Hattmannsdorfer, Bundesvorsitzende der Jungen Wirtschaft Bettina Dorfer-Pauschenwein, and delegations from the Federal Ministry for Economic Affairs and Energy and the Austrian Federal Economic Chamber to NovoArc GmbH.
We are excited to announce the start of our Lipidosa Project in collaboration with Joanneum Graz, running from July 2025 to June 2027, focused on the pharmacological characterization of tetraetherlipid formulations for oral administration.
We are proud to announce our participation in the D2R Project Spotlight, a collaborative effort with leading researchers from McGill University, Dalhousie University, the University of Calgary, and RNA Technologies and Therapeutics.
We are proud to share that our Co-founder and CPO, Oliver Spadiut, delivered an inspiring talk during the Innovation Session at the Advanced Therapies Conference 2025 in London.
NovoArc GmbH has won the Phönix Start-up Award! Receiving this prestigious prize at the Haus der Industrie Industriellenvereinigung was an unforgettable moment in an amazing atmosphere – a recognition of the hard work we’ve put in over the past years.
Excited to be attending BIO-Europe in Stockholm, Sweden from November 4–6, 2024! Looking forward to connecting and exchanging insights. See you there!
8th International Symposium on Phospholipids in Pharmaceutical Research
CEO Dr. David Wurm had the pleasure of speaking at the 8th International Symposium on Phospholipids in Pharmaceutical Research last week, where there was even a dedicated session on Tetraether lipids an exciting development for a field that’s gaining momentum. A big thank you to everyone who made the event a success! Looking forward to more exciting developments in the future.
We had the honor of welcoming Federal Minister Polaschek to our company. "I am very pleased with the impressive progress NovoArc has made. They are a prime example of a successful academic spin-off," Federal Minister Polaschek.
New publication: improved transfection efficiency of mRNA-LNP
We're thrilled to announce that our latest research has been published online in the European Journal of Pharmaceutics and Biopharmaceutics!
In cooperation with TU Wien our team at NovoArc was able to demonstrate an innovative approach to enhance transfection efficiency for mRNA in in vitro studies. This advancement holds great promise for the future of vaccination and gene therapy, opening new pathways for medical treatments and patient care.
We use cookies on our website. They help us to improve this website and the user experience (tracking cookies). You can decide for yourself whether you want to allow them.
